<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:regsci-ojs-tamu.tdl.org:article/21</identifier>
				<datestamp>2023-04-06T21:25:53Z</datestamp>
				<setSpec>regsci:SA</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A Comprehensive Analysis of Factors That Contribute to Conditional Approval and All-Case Surveillance Designations That Subsequently Lead to Shortening of Review Times in Japan</dc:title>
	<dc:creator xml:lang="en">Shibata, Shoyo</dc:creator>
	<dc:creator xml:lang="en">Uemura, Ryotaro</dc:creator>
	<dc:creator xml:lang="en">Chiba, Koji</dc:creator>
	<dc:creator xml:lang="en">Suzuki, Takeshi</dc:creator>
	<dc:subject xml:lang="en">drug development</dc:subject>
	<dc:subject xml:lang="en">all-case surveillance</dc:subject>
	<dc:subject xml:lang="en">conditional approval</dc:subject>
	<dc:subject xml:lang="en">regulatory review time</dc:subject>
	<dc:subject xml:lang="en">drug lag</dc:subject>
	<dc:subject xml:lang="en">PMDA</dc:subject>
	<dc:subject xml:lang="en">Regulatory Science</dc:subject>
	<dc:description xml:lang="en">We examined conditional approval and all-case surveillance designations for new molecular entities investigated between 2000 and 2014 in Japan. Using univariate or multivariate logistic-regression analysis, this study attempted to clarify profiles that affect the receipt of these designations, and to provide guidance for effectively using conditional approval and all-case surveillance designations. Analysis showed that the highest number of drugs to which these systems were applied was category L (“Antineoplastic and immunomodulating agents”) of the Anatomical Therapeutic Chemical Classification System. Orphan drug designation (ODD) and L drugs were significantly correlated with the receipt of both conditional approval and all-case surveillance. These designations shortened the review time. Positive factors that shortened the period of review included ODD, using global data, and joining a global study. Bridging strategy was the only negative factor. Utilization of this Japan-specific PMS system can shorten drug lag, thereby securing the safety of Japanese subjects.https://doi.org/10.21423/jrs-v04n01p001 (DOI assigned 7/23/2019)</dc:description>
	<dc:publisher xml:lang="en">Office of the Texas State Chemist</dc:publisher>
	<dc:date>2016-03-11</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Dry research</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://regsci-ojs-tamu.tdl.org/regsci/article/view/21</dc:identifier>
	<dc:identifier>10.21423/JRS-V04N01P001</dc:identifier>
	<dc:source xml:lang="en">Journal of Regulatory Science; Vol. 4 No. 1 (2016); 1-9</dc:source>
	<dc:source>2377-3537</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/21/32</dc:relation>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/21/121</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
